Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

Kidney Diseases Clinical Trial

Official title:

An Open Label, Multi-Center, Safety and Pharmacokinetic Bridging Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring in Normal and Renal Compromised Subjects for the Evaluation of Kidney Function

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05777174
• Other study ID #: 100-201
• Status: Recruiting
• Phase: Phase 3
• Start date: March 20, 2023
• Est. completion date: April 2024

Study information

• Verified date: February 2024
• Source: MediBeacon
• Contact: Richard B. Dorshow, PhD
• Phone: 314-735-0967
• Email: rbdorshow[@]medibeacon.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to establish that the MB-102 transdermal fluorescence-measured Glomerular Filtration Rate (GFR) using the MediBeacon® Measurement System with the Transdermal Glomerular Filtration Rate (TGFR) reusable sensor with disposable adhesive ring is comparable to the plasma-measured MB-102 GFR in normal and compromised renal function participants with different skin color types.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 220
• Est. completion date: April 2024
• Est. primary completion date: April 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Eligible female non-pregnant participants who are either not of child-bearing potential or willing to use adequate contraception during the trial

• Males must be willing to practice abstinence or utilize adequate contraception from dosing day to at least 7 days post-dose

• For women of childbearing potential, the participant should have a negative serum pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly i.e. abstinence, oral contraceptive either combined or progesterone alone; injectable progesterone, implants of levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive patches, IUD device or system or male partner sterilization

• Men will not donate sperm during the study and for 1 month following the last dose of study drug.

• Participants who are capable of directly providing informed consent and who can comply with the requirements and restrictions required by the protocol

• Adequate venous access sufficient to allow blood sampling per protocol requirements

Exclusion Criteria:

• Participants positive for COVID-19 at the time of dosing

• Recent donation or loss of blood or plasma: 100 mL to 499 mL within 30 days prior to the initial dose of the study medication; or more than 499 mL within 56 days prior to the initial dose of study medication

• Non-steroidal anti-inflammatory (NSAID) use within 3 days of MB-102 dosing

• The participant has participated in a clinical trial and has received an investigational product within the following time ranges: prior to the first dosing day in the current study: either 30 days or 5 half-lives of the investigational product (whichever duration is longer).

• History of skin sensitivity to adhesives (e.g. Band-Aids, surgical tape)

• History of severe allergic hypersensitivity reactions (unacceptable adverse events) or anaphylactoid reaction to any allergen including drugs, MB-102 or other related products (intolerance to a drug is not considered a drug allergy).

• Any characteristics which, in the opinion of the investigator, makes the participant a poor candidate for participation in the clinical trial

• Significant scaring, tattoos or alterations in pigmentation on the sternum or other sensor location testing areas that would alter sensor readings versus other areas of the skin

• Use of tanning sprays, tanning products etc. on the upper chest within 2 weeks of dosing day

• Use make-up, lotions, Vaseline or other products on the area of the upper chest on the day prior to or the day of dosing

• Any serious or uncontrolled medical disorder, active infection, physical exam finding, laboratory finding, or psychiatric condition that in the opinion of the investigator would limit the participant's ability to complete study requirements or may put the participant at increased risk or compromise the interpretability of study results.

• Currently receiving dialysis

• Currently anuric

• Positive serum pregnancy test

• Participants with an eGFR > 120 mL/min/1.73m^2

Related Conditions & MeSH terms

• Kidney Diseases
• Kidney Failure
• Kidney Injury
• Renal Insufficiency

Intervention

Drug:
• MB-102
130 mg administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30-60 seconds.

Device:
• MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
On treatment day, participants will have the TGFR reusable sensor with disposable adhesive ring placed on their chest, and the MediBeacon® Transdermal GFR Measurement System will be initiated to collect background fluorescence. When this is completed, participants will then receive a single dose of MB-102. Fluorescent measurements will be collected for 12-24 hours. For those with significant renal compromise, fluorescent measurements will continue until the sensor no longer detects MB-102 in the body.

Locations

Country	Name	City	State
United States	PPD	Austin	Texas
United States	Research by Design, LLC	Chicago	Illinois
United States	Centricity Research	Columbus	Ohio
United States	Clinical Advancement Center, PLLC	San Antonio	Texas
United States	Endeavor Clinical Trials, LLC	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
MediBeacon

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation of transdermal derived glomerular filtration rate (tGFR) to the plasma-derived indexed glomerular filtration rate (nGFR)	Statistical agreement between tGFR and nGFR will be calculated.	Up to 24 hours
Secondary	Number of participants with treatment-emergent adverse events associated with MB-102 administration	An adverse event is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, temporally associated with the use of a medicinal product, whether or not related to the investigational medical device or drug.	Up to 10 days
Secondary	Number of participants with treatment-emergent adverse events associated with the MediBeacon Transdermal GFR Measurement System device	An adverse event is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, temporally associated with the use of a medicinal product, whether or not related to the investigational medical device or drug.	Up to 10 days